Table 3.
Depression and anxiety levels at baseline and during treatment
| ITT | OT | |||||
| Depression scores | ||||||
| Basal | Week 6 | Week 12 | Basal | Week 6 | Week 12 | |
| GeDep scale1 | 38.3 ± 2.5 | 38.1 ± 2.3 | 36.8 ± 2.3 | 36.9 ± 3.1 | 34.9 ± 2.9 | 34.9 ± 2.9 |
| Zung scale2 | 35.2 ± 1.3 | 33.8 ± 1.4 | 34.2 ± 1.4 | 34.9 ± 1.6 | 34.6 ± 1.7 | 35.0 ± 1.7 |
| Anxiety scores | ||||||
| Basal | Week 6 | Week 12 | Basal | Week 6 | Week 12 | |
| GegDep scale3 | 43.3 ± 2.4 | 41.9 ± 2.3 | 40.8 ± 2.3 | 40.9 ± 2.9 | 38.1 ± 2.9 | 36.8 ± 2.9 |
| Zung scale4 | 37.2 ± 1.1 | 36.7 ± 1.4 | 36.6 ± 1.6 | 34.5 ± 1.4 | 32.4 ± 1.7 | 32.8 ± 1.9 |
Values represent mean ± SD scores in the depression and anxiety scales.
1
Within-subject effect: F (2) = 0.5, P = 0.6; between-subject effect: F (1) = 0.3, P = 0.6;
2
Within-subject effect: F (2) = 0.6, P = 0.6; between-subject effect: F (1) = 0.6, P = 0.5;
3
Within-subject effect: F (2) = 0.5, P = 0.6; between-subject effect: F (1) = 0.9, P = 0.4;
4
Within-subject effect: F (2) = 0.8, P = 0.5; between-subject effect: F (1) = 3.1, P = 0.09. OT: Other treatments; ITT: Isotretinoine.